POLYMYALGIA RHEUMATICA – PIPELINE REVIEW, 2019

Polymyalgia rheumatica is a common inflammatory disorder that leads to muscle ache, stiffness, and inflammation in shoulders, neck, and hips lasting longer than 45 minutes, especially in the morning. The symptoms appear quickly and become worse in the morning. Polymyalgia rheumatica is an age-related disorder. Older people of 60 years and above are at higher risk of polymyalgia rheumatic. It is rarely observed in people under 50 years of age. The cause of polymyalgia rheumatica is uncertain but genetic and environmental factors are thought to be responsible for the development of this condition. Symptoms of polymyalgia rheumatica include muscle stiffness for a longer duration, extreme tiredness, loss of appetite, and weight loss.

Current treatment of polymyalgia rheumatic includes medications, supplements, and physical therapy. The treatment focuses on the reduction of pain and inflammation. Steroids are the first line of treatment for polymyalgia rheumatic as they are powerful anti-inflammatory drugs. Other medications include non-steroidal anti-inflammatory drugs like ibuprofen and naproxen, calcium and vitamin D supplements, and methotrexate.

Increasing prevalence of polymyalgia rheumatica and demand for non-invasive treatment options is encouraging the pharmaceutical companies and research institutes for developing novel treatment options for polymyalgia rheumatica. For instance; Sarilumab SAR153191, which is being studied by Sanofi is currently in phase 3 clinical trials for the study of safety and efficacy of Sarilumab SAR153191 in patients with polymyalgia rheumatica.

At present, around 45% of the pipeline candidates for polymyalgia rheumatica are in phase 3 clinical stage. More than half of the studies are sponsored by research institutes.

Report Description 

The report on ‘Polymyalgia Rheumatica – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Polymyalgia Rheumatica. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Polymyalgia Rheumatica. 

The report on ‘Polymyalgia Rheumatica – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• A thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target
• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration
• Overview of dormant and discontinued pipeline products
• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products
• Overview of the latest developments; news articles, press releases, and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.
• Desk research sources include global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on a comprehensive overview of the R&D activity and pipeline products for Polymyalgia Rheumatica.
• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players
• Identify the focus of leading players in relation to R&D for Polymyalgia Rheumatica.
• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business
• Analyze the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary